Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551043 · ClinicalTrials.gov registry record · Phase 1
Allo CART-19 Protocol
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01551043: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT01551043 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01551043, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).
Interventions
- BIOLOGICAL CART-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551043
The ClinicalTrials.gov registry entry for NCT01551043 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART-19 is the first listed.
NCT01551043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551043 about?
NCT01551043 is a clinical study titled "Allo CART-19 Protocol". The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).
What is the current status of trial NCT01551043?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2010-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01551043?
The interventions under investigation include: CART-19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01551043?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.